Proceedings from a satellite symposium during the 42nd annual
San Antonio Breast Cancer Symposium. Featuring perspectives from Dr
Harold J Burstein, Dr Matthew Goetz, Prof Stephen RD Johnston and
Dr Joseph A Sparano.
Introduction
Program Overview: Dr Love (00:00)
Use of Genomic Classifiers to Inform Therapeutic
Decision-Making for Patients with ER-Positive Localized Breast
Cancer (BC)
Case (Dr Goetz): A premenopausal woman in her
early 40s with a 1.4-cm, ER-positive, HER2-negative, node-negative
IDC and a 21-gene Recurrence Score® of 9 (1:14)
Case (Prof Johnston): A woman in her late 30s
with a 1.8-cm, ER-positive, HER2-negative, node-negative IDC and an
intermediate 21-gene Recurrence Score (9:24)
Case (Dr Burstein): A woman in her late 50s
with a 1.3-cm, ER-positive, HER2-negative IDC and 1 positive
sentinel lymph node (11:11)
Faculty Presentation: Dr Sparano (13:57)
Optimizing the Use of CDK4/6 Inhibitors in the
Management of ER-Positive Metastatic BC (mBC)
Case (Dr Goetz): A woman in her mid-40s
develops liver and bone metastases near the completion of 5 years
of letrozole for ER-positive BC (34:52)
Faculty Presentation: Dr Goetz (38:28)
Case (Dr Sparano): A man in his late 40s
presents with de novo ER-positive, HER2-negative mBC to the lung
and bones and receives abemaciclib and tamoxifen (51:17)
Current and Future Management of ER-Positive mBC After
Disease Progression on CDK4/6 Inhibition
Case (Dr Sparano): A woman in her early 40s
with ER-positive, HER2-negative mBC who has experienced disease
progression on multiple lines of endocrine therapy is found to have
a PIK3CA mutation (56:48)
Case (Dr Goetz): A woman in her mid-40s
receives abemaciclib/fulvestrant for ER-positive, HER2-negative mBC
but experiences disease progression after 2 years (57:32)
Faculty Presentation: Dr Burstein (1:00:03)
Novel Applications of CDK4/6 Inhibitors; Ongoing
Clinical Trials
Faculty Presentation: Prof Johnston (1:16:55)
Case (Prof Johnston): A woman in her mid-30s
who has experienced disease progression on multiple lines of
therapy, including most recently palbociclib/fulvestrant, undergoes
multiplex testing, which reveals ESR1 and PIK3CA mutations
(1:30:49)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.